Belgium-based ExeVir Bio BV has appointed Michel Kazatchkine and Stef Heylen to its board of directors. The company is developing nanobody therapies providing broad protection against viral infections, including a lead candidate targeting for coronaviruses. Prof Kazatchkine brings over 35 years of experience in global health, and is Emeritus Professor of Immunology at René Descartes University in Paris. He is also a senior fellow with the Global Health Centre of the Graduate Institute for International and Development Studies in Geneva. Dr Heylen brings over 30 years of pharmaceutical drug development and executive management experience, having worked at companies including Janssen Pharmaceutica NV and the Johnson & Johnson Pharmaceuticals Group.
ExeVir announced the appointments on 3 November 2020.
Copyright 2020 Evernow Publishing Ltd